Zhong Yan Gan

Zhong Yan Gan

Auto-generated profile, based on publicly available information

Zhong Yan Gan

Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
TKTheresa Klemm
Theresa Klemm
GEGregor Ebert
Gregor Ebert
DCDale J Calleja
Dale J Calleja
CACody C Allison
Cody C Allison
LRLachlan W Richardson
Lachlan W Richardson
DKDavid Komander
David Komander
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

7 January 2021 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
MSMarlene F. Schmidt
Marlene F. Schmidt
ZGZhong Yan Gan
Zhong Yan Gan
DKDavid Komander
David Komander
GDGrant Dewson
Grant Dewson
Neurodegenerative diseases are characterised by progressive damage to the nervous system including the selective loss of vulnerable populations of neurons leading to motor symptoms and cognitive decline. Despite millions of people being affected worldwide, there are still no drugs that block the neurodegenerative process to stop or slow disease progression. Neuronal death in these diseases is often linked to the misfolded proteins that aggregate within the brain (proteinopathies) as a result of disease-related gene mutations or abnormal protein homoeostasis. There are two major degradation pathways to rid a cell of unwanted or misfolded proteins to prevent their accumulation and to maintain the health of a cell: the ubiquitin–proteasome system and the autophagy–lysosomal pathway. Both of these degradative pathways depend on the modification of targets with ubiquitin. Aging is the primary risk factor of most neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. With aging there is a general reduction in proteasomal degradation and autophagy, and a consequent increase of potentially neurotoxic protein aggregates of β-amyloid, tau, α-synuclein, SOD1 and TDP-43. An often over-looked yet major component of these aggregates is ubiquitin, implicating these protein aggregates as either an adaptive response to toxic misfolded proteins or as evidence of dysregulated ubiquitin-mediated degradation driving toxic aggregation. In addition, non-degradative ubiquitin signalling is critical for homoeostatic mechanisms fundamental for neuronal function and survival, including mitochondrial homoeostasis, receptor trafficking and DNA damage responses, whilst also playing a role in inflammatory processes. This review will discuss the current understanding of the role of ubiquitin-dependent processes in the progressive loss of neurons and the emergence of ubiquitin signalling as a target for the development of much needed new drugs to treat neurodegenerative disease.

21 December 2021 in Nature
Verified
Journal Article
Open access
PDF file
ZGZhong Yan Gan
Zhong Yan Gan
SCSylvie Callegari
Sylvie Callegari
SCSimon Cobbold
Simon Cobbold
TCThomas R. Cotton
Thomas R. Cotton
MMMichael J. Mlodzianoski
Michael J. Mlodzianoski
DKDavid Komander
David Komander
Mutations in the protein kinase PINK1 lead to defects in mitophagy and cause autosomal recessive early onset Parkinson’s disease1,2. PINK1 has many unique features that enable it to phosphorylate ubiquitin and the ubiquitin-like domain of Parkin3,4,5,6,7,8,9. Structural analysis of PINK1 from diverse insect species10,11,12 with and without ubiquitin provided snapshots of distinct structural states yet did not explain how PINK1 is activated. Here we elucidate the activation mechanism of PINK1 using crystallography and cryo-electron microscopy (cryo-EM). A crystal structure of unphosphorylated Pediculus humanus corporis (Ph; human body louse) PINK1 resolves an N-terminal helix, revealing the orientation of unphosphorylated yet active PINK1 on the mitochondria. We further provide a cryo-EM structure of a symmetric PhPINK1 dimer trapped during the process of trans-autophosphorylation, as well as a cryo-EM structure of phosphorylated PhPINK1 undergoing a conformational change to an active ubiquitin kinase state. Structures and phosphorylation studies further identify a role for regulatory PINK1 oxidation. Together, our research delineates the complete activation mechanism of PINK1, illuminates how PINK1 interacts with the mitochondrial outer membrane and reveals how PINK1 activity may be modulated by mitochondrial reactive oxygen species.

18 April 2025 in Science
Verified
Journal Article
Closed access
SCSylvie Callegari
Sylvie Callegari
NKNicholas S. Kirk
Nicholas S. Kirk
ZGZhong Yan Gan
Zhong Yan Gan
TDToby Dite
Toby Dite
SCSimon Cobbold
Simon Cobbold
DKDavid Komander
David Komander
Mutations in the ubiquitin kinase PINK1 cause early-onset Parkinson’s disease, but how PINK1 is stabilized at depolarized mitochondrial translocase complexes has remained poorly understood. We determined a 3.1-angstrom resolution cryo–electron microscopy structure of dimeric human PINK1 stabilized at an endogenous array of mitochondrial translocase of the outer membrane (TOM) and voltage-dependent anion channel (VDAC) complexes. Symmetric arrangement of two TOM core complexes around a central VDAC2 dimer is facilitated by TOM5 and TOM20, both of which also bind PINK1 kinase C-lobes. PINK1 enters mitochondria through the proximal TOM40 barrel of the TOM core complex, guided by TOM7 and TOM22. Our structure explains how human PINK1 is stabilized at the TOM complex and regulated by oxidation, uncovers a previously unknown TOM-VDAC assembly, and reveals how a physiological substrate traverses TOM40 during translocation.

16 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KWKelsey S. Whinn
Kelsey S. Whinn
GKGurleen Kaur
Gurleen Kaur
JLJacob Lewis
Jacob Lewis
GSGrant D. Schauer
Grant D. Schauer
SMStefan H. Mueller
Stefan H. Mueller
Harshad GhodkeHarshad Ghodke
Harshad Ghodke
Limited experimental tools are available to study the consequences of collisions between DNA-bound molecular machines. Here, we repurpose a catalytically inactivated Cas9 (dCas9) construct as a generic, novel, targetable protein–DNA roadblock for studying mechanisms underlying enzymatic activities on DNA substrates in vitro. We illustrate the broad utility of this tool by demonstrating replication fork arrest by the specifically bound dCas9–guideRNA complex to arrest viral, bacterial and eukaryotic replication forks in vitro.

19 January 2024 in Science Advances
Verified
Journal Article
Open access
ZGZhong Yan Gan
Zhong Yan Gan
SCSylvie Callegari
Sylvie Callegari
TNThanh N. Nguyen
Thanh N. Nguyen
NKNicholas S. Kirk
Nicholas S. Kirk
ALAndrew Leis
Andrew Leis
DKDavid Komander
David Komander
The ubiquitin kinase PINK1 accumulates on damaged mitochondria to trigger mitophagy, and PINK1 loss-of-function mutations cause early onset Parkinson’s disease. Nucleotide analogs such as kinetin triphosphate (KTP) were reported to enhance PINK1 activity and may represent a therapeutic strategy for the treatment of Parkinson’s disease. Here, we investigate the interaction of PINK1 with nucleotides, including KTP. We establish a cryo-EM platform exploiting the dodecamer assembly of Pediculus humanus corporis ( Ph ) PINK1 and determine PINK1 structures bound to AMP-PNP and ADP, revealing conformational changes in the kinase N-lobe that help establish PINK1’s ubiquitin binding site. Notably, we find that KTP is unable to bind Ph PINK1 or human ( Hs ) PINK1 due to a steric clash with the kinase “gatekeeper” methionine residue, and mutation to Ala or Gly is required for PINK1 to bind and use KTP as a phosphate donor in ubiquitin phosphorylation and mitophagy. Hs PINK1 M318G can be used to conditionally uncouple PINK1 stabilization and activity on mitochondria.